- Home
- ALAR vs ZNTL Comparison
ALAR vs ZNTL Comparison
Compare ALAR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALAR | ZNTL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 118.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALAR | ZNTL |
|---|---|---|
| Price | $8.64 | $2.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $27.00 | $5.87 |
| AVG Volume (30 Days) | 72.5K | ★ 2.6M |
| Earning Date | 11-26-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $36,305,000.00 | $26,865,000.00 |
| Revenue This Year | $31.17 | N/A |
| Revenue Next Year | $30.14 | N/A |
| P/E Ratio | $52.71 | ★ N/A |
| Revenue Growth | ★ 15.03 | N/A |
| 52 Week Low | $5.45 | $1.01 |
| 52 Week High | $18.00 | $3.95 |
Technical Indicators
Market Signals| Indicator | ALAR | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 64.13 |
| Support Level | $9.20 | $1.31 |
| Resistance Level | $10.19 | $3.95 |
| Average True Range (ATR) | 0.59 | 0.38 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 31.06 | 59.28 |
Price Performance
Historical ComparisonAbout ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.